Fig. 7
From: IKZF1 as a potential therapeutic target for dendritic cell-mediated immunotherapy in IgA nephropathy
Lenalidomide treatment relieve anti-Thy1 nephritis kidney injury. (A) Schematic illustration Lenalidomide (Len) administration for anti-Thy1 rats. Male rats were administered intraperitoneal injections of normal saline and 12.5 mg/kg Len for 5 days. (B-D) Renal function parameters BUN, SCR and UACR were assessed. (E)Representative kidney images following PAS staining after the Len treatments. (F) Quantification of the number of nuclei per glomerulus after Len treatment in (E). (G) Immunohistochemical staining of cell proliferation markers GATA3 and PCNA in the kidney from anti-Thy1 nephritis rats. (H) Western blotting of the mesangial cell proliferation marker PCNA, GATA3, FN and α-SMA. (I-J) Representative immunofluorescence staining and quantification of α-SMA images in kidneys after Len treatment. α-SMA (red), Collagen-I (green) and DAPI (nuclear; blue). Data are presented as means ± SEM, n = 5; *P< 0.05, **P< 0.01, ***P< 0.001. Scale bar = 50 μm